Product Details
| Product Name:
E7820 |
CAS No.:
289483-69-8 |
| Purity:
99.11% |
Supply Ability:
10g |
| Release date:
2024/11/17 |
Product Introduction
Bioactivity
| 名稱 | E7820 |
| 描述 | E7820 (ER68203-00) is an angiogenesis inhibitor by suppressing integrin a2 (a cell adhesion molecule expressed on endothelial cells). |
| 體外活性 | E7820 inhibits proliferation of HUVEC induced by either bFGF (IC50: 0.10 μg/mL) and VEGF (IC50: 0.081 μg/mL) in serum-free medium. E7820 also inhibits both bFGF- (IC50: 0.20 μg/mL) and VEGF-driven (IC50: 0.24 μg/mL) tube formation of HUVEC in this assay[3]. |
| 體內(nèi)活性 | E7820 (50 mg/kg) with erlotinib has a significantly synergistic antitumor effect in three xenograft models without severe body weight loss. E7820 (50 mg/kg) and erlotinib decrease MVD and enhance apoptosis in tumor-associated endothelial cells, inhibit tumor cell proliferation and enhanced apoptosis, and enhance inhibition of cell proliferation and apoptosis through activation of both intrinsic and extrinsic apoptosis pathways in human NSCLC xenograft models[1]. E7820 shows anti-tumor activity at doses of 50, 100, and 200 mg/kg in the tumor growth and α2-integrin expression experiments[2]. E7820 (50, 100, and 200 mg/kg) inhibits tumor growth in a dose-dependent manner in all s.c. xenograft models. E7820 completely inhibits s.c. tumor growth of LoVo tumor cells and also regresses the tumor mass of KP-1 tumor cells at the dosages of both 100 and 200 mg/kg[3]. |
| 存儲條件 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : Insoluble
DMSO : 33 mg/mL
|
| 關(guān)鍵字 | cell | tumor | E 7820 | WiDr | derivative | Integrin | E7820 | colorectal | LoVo | inhibit | Inhibitor | sulfonamide | HUVEC | E-7820 | endothelium |
| 相關(guān)產(chǎn)品 | K34c hydrochloride | Tirofiban hydrochloride monohydrate | Lifitegrast | Elarofiban TFA | Cyclo(-RGDfK) | Tirofiban | Bestatin hydrochloride | RO0270608 | ICAM-1-IN-1 | Gantofiban |
| 相關(guān)庫 | 經(jīng)典已知活性庫 | 抗癌臨床化合物庫 | 藥物功能重定位化合物庫 | 抑制劑庫 | 口服活性化合物庫 | 臨床期小分子藥物庫 | 已知活性化合物庫 | 抗癌化合物庫 | 抗癌藥物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:301356-95-6
$46.00 / 5mg
-
-
CAS:885101-89-3
$29.00 / 10mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States